Global Gene Panel Market - A Systematic Review and Meta-analysis of entire Targeted Gene Sequencing Industry Forecast 2018-2023

The Global Gene Panel Market is expected to reach an approximate CAGR of ~19% during the forecast period. The rising prevalence of genetic diseases and cancer is the key factor for the market to grow. According to the Cancer Research U.K., in 2012, 14.1 million cases of cancer were diagnosed all over the world, and 8.2 million died due to cancer. It also projected that the number of cancer patients is expected to reach 23.6 million by 2030.

The increase in adoption of genetic testing, rising company initiatives, technological advancements such as Next Generation Sequencing (NGS) system, and the need for efficient prenatal diagnosis are important factors influencing the growth of the market. It is estimated that Next-Generation Sequencing (NGS) enables to sequence the entire DNA and RNA sequences in order to detect the presence of any mutation in the genome. With these diagnostic benefits of gene panel, the market is projected to grow rapidly.

However, factors such as high cost of testing followed by erroneous results and security concerns for the genetic data are estimated to hinder the market growth during the forecast period.

Get Exclusive Sample Report Here https://www.marketresearchfuture.com/sample_request/6100

Global Gene Panels Market – Key Players:

• Thermo Fisher Scientific (U.S.)
• Hoffmann-La Roche AG (Switzerland)
• Illumina, Inc.
• BGI (China)
• Agilent Technologies (U.S.)
• Integrated DNA Technologies (IDT) (U.S.)
• Eurofins Scientific (U.S.)
• QIAGEN (Germany)
• GENEWIZ
• Novogene Corporation (China)
• Personalis (U.S.)
• GATC Biotech AG (GATC Biotech) (Germany)
• ArcherDx (U.S.)
• CENTOGENE AG

Get Amazing Discount on Report @ https://www.marketresearchfuture.com/check-discount/6100

Global Gene Panels Market – Regional Analysis

The gene panel market is dominated by Americas owing to the increasing prevalence of chronic diseases such as cancer. The American Cancer Society, Inc., estimated that there would be 1,735,350 new cancer cases diagnosed in the United States in 2018. Increasing cancer care expenditure in the United States is likely to drive the market growth. The U.S. Department of Health and Human Services estimated USD147.3 billion national expenditures for cancer care in 2017. The growing biotech sector in the U.S. also drives the market growth in this region. According to Statista (2015), around 108 billion U.S. dollars revenue was generated from the biotech sector in U.S. Additionally, the presence of the highest concentration of biotech companies in the U.S. influences the growth of the market.

It is estimated that Europe stood second in the global gene panel market. Increasing research and development activities for cancer and congenital diseases drive the growth of the market in Europe.
According to Eurostat, in 2014, 26.4% of the total death number was due to cancer. These concerns, enhance the research and development activities in Europe, thereby influencing the growth of the market.

Asia Pacific will witness growth for the gene panel market owing to growing prevalence of cancer. China accounts for the largest prevalence of cancer in the Asia Pacific region. The American Cancer Society, Inc., in 2012 estimated that China accounted for 48.9% of the total cancer cases in South-Eastern Asia and India and Japan accounted for 16.2% and 11.2%, respectively. Additionally, increasing health expenditure in Asia Pacific influences the market growth.

The Middle East and Africa is expected to witness growth at a slower pace due to the less exposure to healthcare services and low per capita healthcare expenditures in the African region. Whereas, the Middle Eastern market is estimated to be growing at a faster rate due to increase in government initiatives, new health insurance policies, and digital health services during the forecast period

Global Gene Panels Market - Segmentation

The global gene panel market is segmented on the basis of product and service, technique, design, application, and end-user. The gene panel market, by product and service, is segmented into test kits and testing services. The global gene panel market by technique is segmented into the amplicon-based approach and hybridization-based approach. The design segment is segmented into predesigned gene panels and customized gene panels. On the basis of application, the market is categorized into cancer risk assessment, pharmacogenetics, diagnosis of congenital disorders, and other applications. The cancer risk assessment segment is further sub-segmented into syndrome-specific gene panels, high-penetrance gene panels, high and moderate-penetrance gene panels, and comprehensive cancer risk panels. On the basis of end-user, the market is categorized into hospitals, diagnostic laboratories, research and academic institutes, and pharmaceutical and biotechnology companies.

Major Table of Content

Chapter 1. Report Prologue

Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations

Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation

Chapter 4. Market Dynamics

TOC Continued….

To Know More Enquire @ https://www.marketresearchfuture.com/enquiry/6100

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: salesteam@marketresearchfuture.com

This release was published on openPR.